275 related articles for article (PubMed ID: 29104121)
1. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.
Janssen HLA; Brunetto MR; Kim YJ; Ferrari C; Massetto B; Nguyen AH; Joshi A; Woo J; Lau AH; Gaggar A; Subramanian GM; Yoshida EM; Ahn SH; Tsai NCS; Fung S; Gane EJ
J Hepatol; 2018 Mar; 68(3):431-440. PubMed ID: 29104121
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment.
Agarwal K; Ahn SH; Elkhashab M; Lau AH; Gaggar A; Bulusu A; Tian X; Cathcart AL; Woo J; Subramanian GM; Andreone P; Kim HJ; Chuang WL; Nguyen MH
J Viral Hepat; 2018 Nov; 25(11):1331-1340. PubMed ID: 29851204
[TBL] [Abstract][Full Text] [Related]
3. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.
Gane EJ; Lim YS; Gordon SC; Visvanathan K; Sicard E; Fedorak RN; Roberts S; Massetto B; Ye Z; Pflanz S; Garrison KL; Gaggar A; Mani Subramanian G; McHutchison JG; Kottilil S; Freilich B; Coffin CS; Cheng W; Kim YJ
J Hepatol; 2015 Aug; 63(2):320-8. PubMed ID: 25733157
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C.
Lawitz E; Gruener D; Marbury T; Hill J; Webster L; Hassman D; Nguyen AH; Pflanz S; Mogalian E; Gaggar A; Massetto B; Subramanian GM; McHutchison JG; Jacobson IM; Freilich B; Rodriguez-Torres M
Antivir Ther; 2015; 20(7):699-708. PubMed ID: 25105516
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study.
Gane E; Verdon DJ; Brooks AE; Gaggar A; Nguyen AH; Subramanian GM; Schwabe C; Dunbar PR
J Hepatol; 2019 Nov; 71(5):900-907. PubMed ID: 31306680
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B.
Lok AS; Pan CQ; Han SH; Trinh HN; Fessel WJ; Rodell T; Massetto B; Lin L; Gaggar A; Subramanian GM; McHutchison JG; Ferrari C; Lee H; Gordon SC; Gane EJ
J Hepatol; 2016 Sep; 65(3):509-16. PubMed ID: 27210427
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression.
Gane EJ; Dunbar PR; Brooks AE; Zhang F; Chen D; Wallin JJ; van Buuren N; Arora P; Fletcher SP; Tan SK; Yang JC; Gaggar A; Kottilil S; Tang L
J Hepatol; 2023 Mar; 78(3):513-523. PubMed ID: 38133554
[TBL] [Abstract][Full Text] [Related]
9. TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.
Boni C; Vecchi A; Rossi M; Laccabue D; Giuberti T; Alfieri A; Lampertico P; Grossi G; Facchetti F; Brunetto MR; Coco B; Cavallone D; Mangia A; Santoro R; Piazzolla V; Lau A; Gaggar A; Subramanian GM; Ferrari C
Gastroenterology; 2018 May; 154(6):1764-1777.e7. PubMed ID: 29378197
[TBL] [Abstract][Full Text] [Related]
10. Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist.
Lopatin U; Wolfgang G; Tumas D; Frey CR; Ohmstede C; Hesselgesser J; Kearney B; Moorehead L; Subramanian GM; McHutchison JG
Antivir Ther; 2013; 18(3):409-18. PubMed ID: 23416308
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U
Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752
[TBL] [Abstract][Full Text] [Related]
12. Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1.
Riddler SA; Para M; Benson CA; Mills A; Ramgopal M; DeJesus E; Brinson C; Cyktor J; Jacobs J; Koontz D; Mellors JW; Laird GM; Wrin T; Patel H; Guo S; Wallin J; Boice J; Zhang L; Humeniuk R; Begley R; German P; Graham H; Geleziunas R; Brainard DM; SenGupta D
Clin Infect Dis; 2021 Jun; 72(11):e815-e824. PubMed ID: 33043969
[TBL] [Abstract][Full Text] [Related]
13. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees.
Lanford RE; Guerra B; Chavez D; Giavedoni L; Hodara VL; Brasky KM; Fosdick A; Frey CR; Zheng J; Wolfgang G; Halcomb RL; Tumas DB
Gastroenterology; 2013 Jun; 144(7):1508-17, 1517.e1-10. PubMed ID: 23415804
[TBL] [Abstract][Full Text] [Related]
14. JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection.
Zoulim F; Lenz O; Vandenbossche JJ; Talloen W; Verbinnen T; Moscalu I; Streinu-Cercel A; Bourgeois S; Buti M; Crespo J; Manuel Pascasio J; Sarrazin C; Vanwolleghem T; Shukla U; Fry J; Yogaratnam JZ
Gastroenterology; 2020 Aug; 159(2):521-533.e9. PubMed ID: 32343960
[TBL] [Abstract][Full Text] [Related]
15. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy.
Yuen MF; Heo J; Kumada H; Suzuki F; Suzuki Y; Xie Q; Jia J; Karino Y; Hou J; Chayama K; Imamura M; Lao-Tan JY; Lim SG; Tanaka Y; Xie W; Yoon JH; Duan Z; Kurosaki M; Park SJ; Labio ME; Kumar R; Kweon YO; Yim HJ; Tao Y; Cremer J; Elston R; Davies M; Baptiste-Brown S; Han K; Campbell FM; Paff M; Theodore D
J Hepatol; 2022 Oct; 77(4):967-977. PubMed ID: 35714812
[TBL] [Abstract][Full Text] [Related]
16. Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial.
Yuen MF; Zhou X; Gane E; Schwabe C; Tanwandee T; Feng S; Jin Y; Triyatni M; Lemenuel-Diot A; Cosson V; Xue Z; Kazma R; Bo Q
Lancet Gastroenterol Hepatol; 2021 Sep; 6(9):723-732. PubMed ID: 34237271
[TBL] [Abstract][Full Text] [Related]
17. Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection.
Yuen MF; Gane EJ; Kim DJ; Weilert F; Yuen Chan HL; Lalezari J; Hwang SG; Nguyen T; Flores O; Hartman G; Liaw S; Lenz O; Kakuda TN; Talloen W; Schwabe C; Klumpp K; Brown N
Gastroenterology; 2019 Apr; 156(5):1392-1403.e7. PubMed ID: 30625297
[TBL] [Abstract][Full Text] [Related]
18. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
19. Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B.
Lebossé F; Testoni B; Fresquet J; Facchetti F; Galmozzi E; Fournier M; Hervieu V; Berthillon P; Berby F; Bordes I; Durantel D; Levrero M; Lampertico P; Zoulim F
J Hepatol; 2017 May; 66(5):897-909. PubMed ID: 28043874
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial.
Yuen MF; Heo J; Jang JW; Yoon JH; Kweon YO; Park SJ; Tami Y; You S; Yates P; Tao Y; Cremer J; Campbell F; Elston R; Theodore D; Paff M; Bennett CF; Kwoh TJ
Nat Med; 2021 Oct; 27(10):1725-1734. PubMed ID: 34642494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
